Kythera Biopharmaceuticals (KYTH) 10-Q 8 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 16, 2014
Document and Entity Information	'	'
Entity Registrant Name	'KYTHERA BIOPHARMACEUTICALS INC	'
Entity Central Index Key	'0001436304	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	22,656,603
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$93,169,000	$111,518,000
Restricted cash, current portion	1,174,000	5,062,000
Marketable securities	58,230,000	55,540,000
Prepaid expenses and other current assets	2,529,000	1,156,000
Total current assets	155,102,000	173,276,000
Property and equipment, net	108,000	94,000
Other assets	431,000	37,000
Total assets	155,641,000	173,407,000
Current liabilities:	'	'
Accounts payable	3,244,000	3,228,000
Accrued personnel costs	1,239,000	3,114,000
Accrued costs for services	2,859,000	3,191,000
Accrued interest	660,000	375,000
Notes payable, current portion	5,652,000	5,526,000
Deferred development funds	'	2,147,000
Total current liabilities	13,654,000	17,581,000
Notes payable-net of current portion	26,163,000	5,979,000
Other liabilities	6,000	8,000
Total liabilities	39,823,000	23,568,000
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.00001 par value, 5,000,000 shares authorized and none issued and outstanding	'	'
Common stock, $0.00001 par value, 300,000,000 shares authorized, 22,651,000 and 21,745,000 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	'	'
Additional paid in capital	357,472,000	322,052,000
Accumulated other comprehensive income	8,000	4,000
Accumulated deficit	-241,662,000	-172,217,000
Total stockholders' equity	115,818,000	149,839,000
Total liabilities and stockholders' equity	$155,641,000	$173,407,000

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred stock par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	22,651,000	21,745,000
Common stock, shares outstanding	22,651,000	21,745,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating expenses:	'	'
In-process research and development	$52,757,000	'
Research and development	9,980,000	10,034,000
General and administrative	6,121,000	3,725,000
Total operating expenses	68,858,000	13,759,000
Loss from operations	-68,858,000	-13,759,000
Interest income	67,000	28,000
Interest expense	-654,000	-395,000
Net loss	-69,445,000	-14,126,000
Other comprehensive income (loss):	'	'
Unrealized net gain (loss) on marketable securities	8,000	-8,000
Comprehensive loss	($69,437,000)	($14,134,000)
Per share information:	'	'
Net loss, basic and diluted (in dollars per share)	($3.18)	($0.77)
Basic and diluted weighted average shares outstanding	21,836,000	18,335,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating activities	'	'
Net loss	($69,445,000)	($14,126,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Amortization of premium on marketable securities	265,000	94,000
Amortization of debt discount and issuance cost	130,000	85,000
Depreciation	28,000	139,000
Non-cash in-process research and development	53,029,000	'
Stock-based compensation	2,911,000	936,000
Changes in assets and liabilities:	'	'
Prepaid expenses and other assets	-1,767,000	-178,000
Restricted cash	3,888,000	2,157,000
Accounts payable and other accrued liabilities	-1,906,000	-1,307,000
Deferred development funds	-2,147,000	-3,144,000
Other liabilities	-2,000	3,000
Net cash used in operating activities	-15,016,000	-15,341,000
Investing activities	'	'
Purchases of marketable securities	-9,605,000	-32,386,000
Proceeds from sales of marketable securities	6,654,000	'
Investment in property and equipment	-42,000	-34,000
Net cash used in investing activities	-2,993,000	-32,420,000
Financing activities	'	'
Borrowings on credit facility	'	10,000,000
Repayment of notes payable related to credit facility	-1,420,000	'
Proceeds from common stock option exercises	1,080,000	75,000
Net cash (used in) provided by financing activities	-340,000	10,075,000
Net decrease in cash and cash equivalents	-18,349,000	-37,686,000
Cash and cash equivalents at beginning of period	111,518,000	79,311,000
Cash and cash equivalents at end of period	93,169,000	41,625,000
Supplemental disclosures	'	'
Issuance of common stock to Bayer	31,429,000	'
Note payable issued to Bayer at fair value	21,600,000	'
Interest expense paid in cash	$238,000	$291,000

Organization

Organization	3 Months Ended
	Mar. 31, 2014
Organization	'
Organization	'
	1. Organization
	KYTHERA Biopharmaceuticals, Inc. (“KYTHERA” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company’s objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company’s initial focus is on the facial aesthetics market, which comprises the majority of the aesthetics medicine market. The Company’s product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable “double chin.”
	KYTHERA was originally incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005 and its name was changed to AESTHERx, Inc. In July 2006, the Company changed its name to KYTHERA Biopharmaceuticals, Inc.
	Since commencement of operations in August 2005, the Company has devoted substantially all its efforts to the development of ATX-101, recruiting personnel and raising capital. In 2010, the Company entered into a License Agreement with Bayer Consumer Care AG and a Services, Research, Development and Collaboration Agreement with Bayer’s Affiliate, Intendis GmbH, collectively referred to as the collaboration arrangement with Bayer. Bayer Consumer Care AG and Intendis GmbH are referred to jointly as Bayer. On March 7, 2014, the Company entered into an agreement whereby it acquired the rights to develop and commercialize ATX-101 outside of the United States and Canada from Bayer. In connection with this acquisition, the Company recorded a $52,757,000 charge for acquired in-process research and development during the quarter ended March 31, 2014. See Note 6, “Collaborations and Contingencies” for a more detailed discussion of this acquisition.
	The information included in this quarterly report on Form 10-Q should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities Exchange Commission (“SEC”).

Summary_of_Significant_Account

Summary of Significant Accounting Policies and Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies and Basis of Presentation	'
Summary of Significant Accounting Policies and Basis of Presentation	'
	2. Summary of Significant Accounting Policies and Basis of Presentation
	There have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2014 as compared to the significant accounting policies described in the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2013.
	The accompanying financial information for the three months ended March 31, 2014 and 2013 are unaudited. The consolidated financial statements include the consolidated accounts of the Company and its wholly-owned subsidiary, KYTHERA Holdings Ltd. (“KHL”), a Bermuda corporation.  Intercompany accounts and transactions have been eliminated in consolidation.  These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, and include all adjustments, which include only normal recurring adjustments necessary for the fair presentation of our condensed consolidated statement of financial position as of March 31, 2014, our condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2014 and 2013 and our condensed consolidated statements of cash flows for the three months ended March 31, 2014 and 2013. The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other period(s).
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.
	Cash, Cash Equivalents and Marketable Securities
	All highly liquid securities with maturities of 90 days or less from the date of purchase are considered to be cash equivalents. As of March 31, 2014 and December 31, 2013, cash and cash equivalents were comprised of funds invested in cash and money market accounts. The Company maintains cash balances in excess of amounts insured by the FDIC. The accounts are monitored by management to mitigate the risk.
	Investments with maturities of more than 90 days from the date of purchase are considered marketable securities. Marketable securities are stated at fair value. The Company has classified its entire marketable securities portfolio as available-for-sale securities. Accordingly, any unrealized gain or loss on the investments is reported as a component of accumulated other comprehensive income (loss). The amortized cost of these securities is adjusted for amortization of premiums and accretion of discounts to maturity, as applicable. Such amortizations and accretions are included as a component of interest income. The entire marketable securities portfolio is considered available for use in current operations and, accordingly, all such investments are considered current assets although the stated maturity of individual investments may be one year or more beyond the balance sheet date.
	Realized gains and losses, determined on a specific identification basis, and declines in value, if any, judged to be other-than-temporary on available-for-sale securities are reported as a component of interest income. When securities are sold, any associated unrealized gain or loss previously reported in accumulated other comprehensive income (loss) is reclassified out of stockholders’ equity and recorded in the statement of operations and comprehensive loss for the period. Accrued interest and dividends are included in interest income.
	On a quarterly basis, the Company reviews the available-for-sale securities for other-than-temporary declines in fair value below the amortized cost basis.  This evaluation is based on a number of factors including the length of time and extent to which the fair value has been below the cost basis and any adverse conditions related specifically to the security, including any changes to the credit rating of the security. If the Company concludes that an other-than-temporary impairment exists, it recognizes an impairment charge to reduce the investment to fair value and records the related charge as a reduction of interest income. No impairment charges were recognized for the three months ended March 31, 2014 and 2013.
	Property and Equipment
	Property and equipment are recorded at historical cost and consisted of the following:
		March 31,			December 31,
		2014			2013
	Cameras	$	923,000		$	923,000
	Computer hardware and electronics	214,000			182,000
	Furniture and fixtures	244,000			234,000
	Software	21,000			21,000
		1,402,000			1,360,000
	Less accumulated depreciation	(1,294,000		)	(1,266,000		)
		$	108,000		$	94,000
	Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (one to five years). The Company reviews its property and equipment assets for impairment in value whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company had no impairments or disposals during the three months ended March 31, 2014 and 2013.
	Cameras were used in our clinical trials, are fully depreciated as of March 31, 2014 and are being held for disposal.
	Concentration of Credit Risk
	Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. We do not enter into any investment transaction for trading or speculative purposes.
	The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by U.S. government and U.S. government agencies and corporate debt securities and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC. The accounts are monitored by management to mitigate the risk.
	Comprehensive Income (Loss)
	Comprehensive income (loss) is comprised of net loss and other comprehensive income (loss). For the three months ended March 31, 2014 and 2013, the only component of other comprehensive income (loss) are net unrealized gains and losses on marketable securities. There were no reclassifications out of accumulated other comprehensive income (loss) during the three months ended March 31, 2014 and 2013.
	Fair Value of Financial Instruments
	The carrying amounts reported in the accompanying condensed consolidated financial statements for accounts payable and accrued liabilities approximate their fair value because of the short-term nature of these accounts. The fair value of cash equivalents, marketable securities and the notes payable are discussed in Note 7, “Fair Value Measurements.”
	Recent Accounting Pronouncements
	In July 2013, a new accounting standard was issued that requires companies to present in the financial statements an unrecognized tax benefit as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. This standard was adopted prospectively beginning on January 1, 2014 and did not have a material impact on the Company’s consolidated financial statements and related disclosures.

Marketable_Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2014
Marketable Securities	'
Marketable Securities	'
	3. Marketable Securities
	Our marketable securities held as of March 31, 2014 and December 31, 2013 are summarized below:
	Type of security as of March 31, 2014	Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair
				Gains		Losses			Value
	U.S. government agency securities	$	2,000,000	$	2,000	$	—		$	2,002,000
	Corporate debt securities:
	Financial	37,255,000		9,000		(1,000		)	37,263,000
	Industrial	10,025,000		8,000		(4,000		)	10,029,000
	Other	8,942,000		—		(6,000		)	8,936,000
	Total available-for-sale securities	$	58,222,000	$	19,000	$	(11,000	)	$	58,230,000
	Type of security as of December 31, 2013	Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair
				Gains		Losses			Value
	U.S. government agency securities	$	2,000,000	$	3,000	$	—		$	2,003,000
	Corporate debt securities:
	Financial	33,192,000		13,000		(5,000		)	33,200,000
	Industrial	11,081,000		2,000		(3,000		)	11,080,000
	Other	9,263,000		—		(6,000		)	9,257,000
	Total available-for-sale securities	$	55,536,000	$	18,000	$	(14,000	)	$	55,540,000
	There were no material realized gains or losses from the sale of marketable securities during the three months ended March 31, 2014 and 2013. All of our available-for-sale investments that were in an unrealized loss position have been in a continuous unrealized loss position for less than 12 months and had an aggregate fair value of $14,172,000 as of March 31, 2014. The unrealized losses related to corporate debt securities, which the Company plans to hold until maturity, and it is more likely than not that the Company will not be required to sell prior to maturity. Due to the limited duration and severity of the loss, as well as the nature of corporate debt securities, the Company does not consider the investments to be other-than-temporarily impaired at March 31, 2014.
	The maturities of our marketable securities are as follows:
		March 31, 2014				December 31, 2013
		Amortized		Estimated Fair		Amortized			Estimated Fair
		Cost		Value		Cost			Value
	Mature in one year or less	$	50,760,000	$	50,774,000	$	33,279,000		$	33,293,000
	Mature after one year through two years	7,462,000		7,456,000		22,257,000			22,247,000
		$	58,222,000	$	58,230,000	$	55,536,000		$	55,540,000

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2014
Notes Payable	'
Notes Payable	'
	4. Notes Payable
	Notes payable consisted of the following:
		March 31,			December 31,
		2014			2013
	Note payable to Bayer	$	21,645,000		$	—
	Notes payable related to credit facility	10,170,000			11,505,000
		31,815,000			11,505,000
	Less current portion	(5,652,000		)	(5,526,000		)
	Notes payable-net of current portion	$	26,163,000		$	5,979,000
	Note Payable to Bayer
	In March 2014, as part of the agreement to acquire the rights to develop and commercialize ATX-101 outside of the United States and Canada, the Company issued a $51,000,000 unsecured promissory note to Bayer.  The promissory note is subordinated to amounts owed under the Company’s existing credit facility.  Interest is accrued at 5% per annum and is payable on the anniversary date of the note.  The Company has the option of paying 20% of the accrued interest in cash and adding any unpaid interest to the principal amount. The note is due on the ten year anniversary from issuance, with the option to prepay at any point in time without penalty.
	As the note payable to Bayer bears interest at 5%, which is below the borrowing rate currently available to the Company, it was recorded at its fair value of $21,600,000, which is the present value of the future cash flows assuming a borrowing rate of 15%.  The difference between face value and fair value of the note was recorded as a discount and is being amortized over the life of the note utilizing the effective interest method.  The balance of the note payable at March 31, 2014 is as follows:
		March 31, 2014
	Face value of note payable to Bayer	$	51,000,000
	Debt discount at date of issuance	(29,400,000		)
	Amortization of debt discount	45,000
	Note payable to Bayer	$	21,645,000
	Interest expense of $213,000 was recorded during the quarter ended March 31, 2014 related to the note and included amortization of the debt discount of $45,000.  The balance of accrued interest expense at March 31, 2014 was $168,000 and the balance of the remaining unamortized discount was $29,355,000 at March 31, 2014.
	Notes Payable Related to Credit Facility
	On March 21, 2011, the Company executed a debt financing agreement whereby the Company had access to borrow up to $15,000,000 of senior loan financing through January 1, 2012. Subsequently, the credit facility was amended to provide for an extension of the drawdown period. For each draw, the Company shall make six months of interest only payments at a fixed rate of 11.5% followed by 30 months of interest and principal payments at a fixed rate of 8.5% and a final payment of 6% of the amount drawn. Interest expense related to the notes payable is being recorded over the term of the notes utilizing the effective interest method.  The debt is secured by all the Company’s assets, except for the Company’s intellectual property, which is subject to a negative pledge agreement.
	On October 1, 2012, the Company drew $5,000,000 and in November 2012, obtained an extension allowing for the draw of the remaining $10,000,000 in $5,000,000 increments by January 31, 2013 and February 28, 2013. On January 31, 2013 the Company drew down an additional $5,000,000 of available funds under its credit facility and on February 28, 2013, the Company drew the remaining $5,000,000.  As of March 31, 2014 and December 31, 2013, $15,000,000 had been drawn.  There is no further borrowing capacity under this facility as of March 31, 2014.
	Upon entry into the agreement, the Company issued warrants to purchase 34,000 shares of Series C redeemable convertible preferred stock (“Series C Preferred”) at an exercise price of $13.3530. The estimated fair value of the warrants at issuance of approximately $345,000 was recorded as a deferred financing cost offsetting the notes payable liability and is being amortized to interest expense over the expected term of the loan.  Upon extension of the credit facility in December 2011, the Company issued a warrant to purchase up to an additional 86,000 shares of its Series D redeemable convertible preferred stock (“Series D Preferred”) at an exercise price of $13.9040. The estimated fair value of the warrant at issuance of approximately $1,074,000 was recorded as a deferred financing cost offsetting the notes payable liability and is being amortized to interest expense over the expected term of the loan.  Effective immediately prior to the closing of the Company’s initial public offering (“IPO”), the warrants for convertible preferred stock became warrants for common. All warrants were exercised on a cashless basis in December of 2012 resulting in the net issuance of 49,000 shares of common stock.
	Included in interest expense for the three months ended March 31, 2014 and 2013 was amortization of debt issuance costs of $85,000, in each period and interest expense of $356,000 and $310,000, respectively, related to the notes payable. The balance of accrued interest expense at March 31, 2014 and December 31, 2013 was $492,000 and $375,000, respectively. The remaining unamortized debt issuance cost at March 31, 2014 and December 31, 2013 was $651,000 and $736,000, respectively.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity	'
Stockholders' Equity	'
	5. Stockholders’ Equity
	Shares Reserved for Future Issuance
	Shares of the Company’s common stock reserved for future issuance are as follows:
		March 31,
		2014
	Common stock awards outstanding	2,662,000
	Common stock awards available for grant	631,000
	Total common shares reserved for future issuance	3,293,000
	Stock Awards
	In September 2012, the Company’s board of directors approved the 2012 Equity Incentive Award Plan (“the Plan”), which became effective upon completion of our IPO. The Plan provides for the granting of incentive and nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, deferred stock, dividend equivalents, performance awards, stock payments and other stock-based and cash-based awards to its employees, directors, and consultants at the discretion of the compensation committee of the board of directors. The Plan is the successor to the Amended and Restated 2004 Stock Plan. Any remaining shares available for future issuance under the 2004 Stock Plan are available for issuance under the Plan. In addition, the plan reserve will automatically increase annually from January 1, 2013 through January 1, 2022 by an amount equal to the smaller of: (a) 1,512,687 shares, (b) four percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (c) an amount determined by the Company’s board of directors. As of March 31, 2014 and December 31, 2013, a total of 4,094,000 and 3,224,000 shares, respectively, were authorized for grant under the Plan.
	Stock options may be granted with exercise prices not less than the fair market value of the Company’s common stock. Incentive stock options granted to individuals owning more than 10% of the total combined voting power of all classes of stock (“a 10% stockholder”) are exercisable up to five years from the date of grant. The Plan provides that the exercise price of any incentive stock option granted to a 10% stockholder cannot be less than 110% of the estimated fair value of the common stock on the date of grant. Except as set forth above, options granted under the Plan expire no later than ten years from the date of grant. Options granted to employees under the Plan vest over periods determined by the board of directors, which generally vest over four years. Additionally, the Company has granted certain performance-based stock option awards and restricted stock units that vest based on the achievement of certain predetermined milestones. Prior to our IPO, the board of directors determined the estimated fair value of its common stock based on assistance from an independent third-party valuation expert. Since our IPO, the fair market value of the Company’s common stock is the closing share price as reported on the NASDAQ Global Select Market on the date of grant.
	The Company estimates the fair value of its stock-based awards to employees and directors using the Black-Scholes option pricing model. The Black-Scholes model requires the input of complex and subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical public share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price in public markets becomes available. The Company has estimated the expected life of its employee stock options using the “simplified” method, whereby, the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates for periods within the expected life of the option are based on the U.S. Treasury yield curve in effect during the period the options were granted. The Company has never paid, and does not expect to pay dividends in the foreseeable future. The Company also grants restricted stock units and the grant date fair value per share of those awards is equal to the closing stock price on the date of grant.
	The Company is also required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from its estimates. The Company uses historical data to estimate pre-vesting forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent that actual forfeitures differ from the Company’s estimates, the difference is recorded as a cumulative adjustment in the period the estimates were revised. For the three months ended March 31, 2014 and 2013, the Company applied forfeiture rates based on the Company’s historical forfeitures.
	Total equity-based compensation cost recorded in the condensed consolidated statements of operations and comprehensive loss, which includes employee stock-based compensation expense, and the value of options issued to nonemployees and directors for services is allocated as follows:
		Three Months Ended
		March 31,
		2014			2013
	Research and development	$	1,488,000		$	506,000
	General and administrative	1,423,000			430,000
		$	2,911,000		$	936,000
	As of March 31, 2014, there was $21,640,000 of unrecognized compensation expense related to unvested employee stock option agreements, which is expected to be recognized over a weighted-average period of approximately 3.14 years and $4,282,000 related to restricted stock unit agreements which is expected to be recognized over a weighted-average period of approximately 1.51 years. For stock option and restricted stock unit awards subject to graded vesting, the Company recognizes compensation cost on a straight-line basis over the service period for the entire award.
	A summary of stock option activity for the three months ended March 31, 2014 is as follows:
		Number of		Weighted-
		Shares		Average
				Exercise Price
	Outstanding at December 31, 2013	2,273,000		$	14.85
	Granted	481,000		44.12
	Exercised	(195,000	)	5.55
	Cancelled	(35,000	)	21.92
	Outstanding at March 31, 2014	2,524,000		$	21.04
	The Company accounts for stock options issued to nonemployees using a fair value approach. The compensation costs of these arrangements are subject to re-measurement over the vesting terms as earned.
	A summary of restricted stock unit activity for the three months ended March 31, 2014 is as follows:
		Number of		Weighted-
		Shares		Average
				Grant-Date
				Fair Value
	Outstanding at December 31, 2013	63,000		$	27.16
	Granted	89,000		44.02
	Vested	(13,000	)	22.49
	Cancelled	(1,000	)	44.02
	Outstanding at March 31, 2014	138,000		$	38.35

Collaborations_and_Contingenci

Collaborations and Contingencies	3 Months Ended
	Mar. 31, 2014
Collaborations and Contingencies	'
Collaborations and Contingencies	'
	6. Collaborations and Contingencies
	Collaboration Arrangements
	From time to time, the Company enters into collaborative arrangements for its research and development and manufacturing activities. Each collaboration is unique in nature and the Company’s significant agreements are discussed below.
	Bayer
	In August 2010, the Company entered into a license agreement with Bayer Consumer Care AG that provided Bayer with an exclusive license to develop, manufacture and commercialize ATX-101 outside of the United States and Canada. In connection with the License Agreement the Company also entered into a related Services, Research, Development and Collaboration Agreement with Bayer’s affiliate, Intendis GmbH. These agreements were referred to jointly as the collaboration arrangement with Bayer, and Bayer Consumer Care AG and Intendis GmbH are referred to jointly as Bayer. In connection with the entry into the collaboration arrangement, Bayer paid the Company an upfront license fee of approximately $21,319,000 and approximately $22,247,000 for research and development to fund a portion of Bayer’s European Phase III clinical trials. The Company was eligible to receive up to approximately $297,000,000 for certain development, manufacturing, regulatory and commercialization contingent payments upon the achievement by Bayer of specified events under our collaborative arrangement, as well as escalating royalties from the mid- to high-teens on Bayer’s net product sales of ATX-101. The first contingent event-based payment of $15,800,000 was received on May 31, 2012, triggered by the completion of Bayer’s European Phase III clinical trials for ATX-101, the receipt of two consecutive validated manufacturing lots and Bayer’s subsequent decision to pursue continued development and seek regulatory approval of ATX-101. This amount was recorded as revenue upon receipt as all revenue recognition criteria had been met. At this time, Bayer also elected to pursue additional research and development activities related to ATX-101, which are distinct from the original development activities, and subsequently funded $17,400,000 for these additional Bayer development activities. This payment was recorded as restricted cash and deferred development funds and was recognized as an offset to development expense as the restricted cash was utilized to fund Bayer’s development activities. As of March 2014, the Company acquired rights to ATX-101 outside of the United States and Canada from Bayer and no longer expects future revenues from Bayer.
	Amounts to fund collaboration efforts of $22,247,000 and $17,400,000 were recorded as restricted cash and deferred development funds and were recognized as an offset to research and development expenses as the restricted cash was utilized to fund development activities. Amounts recognized as offsets to research and development expenses were $2,391,000 and $3,095,000 for the three months ended March 31, 2014 and 2013, respectively. Deferred development funds remaining at the time that the Company purchased the rights to ATX-101 outside of the United States and Canada in March 2014 of $967,000 were no longer considered restricted cash and were deducted from the one-time charge to in-process research and development, reducing the in-process research and development expense recorded in March 2014. The remaining current portion of restricted cash at March 31, 2014 represents amounts due under the collaboration agreement which have not yet been paid.
	In March 2014, the Company entered into an agreement whereby it acquired the rights to develop and commercialize ATX-101 outside of the United States and Canada from Bayer.  Under the new agreement, KYTHERA Holdings Ltd., a wholly-owned Bermuda subsidiary of KYTHERA Biopharmaceuticals, Inc., purchased these rights. As a result of this agreement, Bayer was issued 698,103 shares of the Company’s common stock valued at $33,000,000 based on an average closing stock price of $47.27 over a period set forth in the agreement.  Additionally, the Company issued an unsecured promissory note for $51,000,000, which is subordinated to amounts owed under our existing credit facility, bears interest at 5% per annum and is payable no later than 2024. Additionally, Bayer is eligible to receive up to $123,800,000 upon the achievement of certain long-term sales milestone payments on annual sales of ATX-101 outside of the United States and Canada.  As of March 31, 2014, the achievement of the related sales levels is not considered to be probable.
	The acquisition date costs allocated to the acquired rights consists of the following:
	Fair value of common stock issued	$	31,429,000
	Fair value of note payable to Bayer	21,600,000
	Other	(272,000		)
	Total in-process research and development	$	52,757,000
	The fair value of the common stock issued is based on the closing price of our common stock on the acquisition date of $45.02 per share. As the note payable to Bayer includes an interest rate which is below the borrowing rate currently available to the Company, it was recorded at its fair value of $21,600,000, which is the present value of the future cash flows assuming a borrowing rate of 15%, which approximates market. Other represents the net impact of the reduction in costs resulting from the residual restricted cash of $967,000 that reverted to the Company, partially offset by $695,000 of transaction costs related to the acquisition.
	As the acquired rights to ATX-101, represent acquired-in-process research and development, with no alternative future uses, the costs allocated to such rights, $52,757,000, were immediately expensed upon acquisition and reflected as in-process research and development in the condensed consolidated statement of operations.
	See Note 4, “Notes Payable” for a more detailed discussion of the promissory note.
	Los Angeles Biomedical Research Institute
	In August 2005, the Company entered into an exclusive license agreement with Los Angeles Biomedical Research Institute at Harbor/UCLA Medical Center, or LA Biomed, pursuant to which it obtained a worldwide exclusive license to practice, enforce and otherwise exploit certain patent rights related to the use of the active ingredient in ATX-101. The exclusive license requires the Company to pay LA Biomed a milestone payment of $500,000 upon receipt of marketing approval of ATX-101, as well as non-royalty sublicense fees equal to 10% of any sublicense income, up to a total of $5,000,000, 50% of which the Company may elect to satisfy through the issuance of capital stock. Additionally, upon commercialization of a licensed product or service, the Company is obligated to pay low- to mid- single digit royalties on net product sales of ATX-101. In August 2010, due to the receipt of the upfront license fee from Bayer, the Company incurred non-royalty sublicense fees of $1,950,000, which was deferred and was recognized as sublicense fee expense on a straight-line basis over the same period as the license income. During 2010, the Company made payments of cash and stock to LA Biomed totaling $390,000 related to the non-royalty sublicense fee incurred. The remainder of $1,560,000 was paid upon the Company’s IPO in 50% cash and 50% stock.
	Additionally, due to the receipt of the contingent event-based payment of $15,800,000 payable from Bayer on May 31, 2012, the Company incurred an additional non-royalty sublicense fee of $1,580,000 payable to LA Biomed, which was paid in 50% cash and 50% stock.
	Contingencies
	From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company is not currently subject to any such matters where there is at least a reasonable possibility that a material loss may have been incurred.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements	'
Fair Value Measurements	'
	7. Fair Value Measurements
	The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:
	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.
	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
	The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.
	At March 31, 2014 and December 31, 2013, the Company had cash equivalents comprised of U.S. Treasury securities money market accounts whose value is based using quoted market prices with no adjustments applied. Accordingly, these securities are classified as Level 1. U.S. Government agency securities and corporate debt securities are measured at fair value using Level 2 inputs. These securities are investment grade with maturity dates of two years or less from the balance sheet date.  The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy. At March 31, 2014, the Company had a note payable with Bayer at a below market interest rate of 5%.  The note was recorded at fair value assuming a discount rate of 15% based on analysis to determine the market rate available to the Company for similar debt.  This analysis was based on significant unobservable inputs including the Company’s cost of equity, the effective interest rate on the credit facility note payable, the rate of public company structured debt arrangements for development companies at a similar stage and other debt issuance by investment firms to similar companies and management’s judgment.  This approach results in the classification of the debt as Level 3 of the fair value hierarchy. There were no material re-measurements to fair value during the three months ended March 31, 2014 and 2013 of financial assets and liabilities that are not measured at fair value on a recurring basis.  There were no transfers of assets or liabilities between the fair value measurement levels during the three months ended March 31, 2014 and 2013.
	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring and non-recurring basis as of March 31, 2014 and December 31, 2013.
		Fair Value Measurement at March 31, 2014 Using:
		Quoted Prices		Significant		Significant		Balance as of
		in Active		Other		Unobservable		March 31,
		Markets for		Observable		Inputs		2014
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Assets:
	Cash equivalents	$	87,818,000	$	—	$	—	$	87,818,000
	U.S. government agency securities	—		2,002,000		—		2,002,000
	Corporate debt securities	—		56,228,000		—		56,228,000
	Total	$	87,818,000	$	58,230,000	$	—	$	146,048,000
	Liabilities:
	Note payable to Bayer	—		—		21,645,000		21,645,000
	Total	$	—	$	—	$	21,645,000	$	21,645,000
		Fair Value Measurement at December 31, 2013 Using:
		Quoted Prices		Significant		Significant		Balance as of
		in Active		Other		Unobservable		December 31,
		Markets for		Observable		Inputs		2013
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Assets:
	Cash equivalents	$	95,537,000	$	—	$	—	$	95,537,000
	U.S. government agency securities	—		2,003,000		—		2,003,000
	Corporate debt securities	—		53,537,000		—		53,537,000
	Total	$	95,537,000	$	55,540,000	$	—	$	151,077,000
	Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the notes payable related to credit facility (Level 2) and note payable to Bayer (Level 3) approximates their fair values.
	The fair values of cash equivalents, accounts payable and accrued liabilities approximate their carrying values due to the short-term nature of these accounts.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Taxes	'
Income Taxes	'
	8. Income Taxes
	There is no provision for income taxes because the Company has incurred operating losses since inception. At March 31, 2014 the Company has concluded that it is more likely than not that the Company may not realize the benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved.
	As of March 31, 2014, the Company does not have any accrued interest or penalties related to uncertain tax positions. The Company’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. The Company does not have any interest or penalties related to uncertain tax positions in income tax expense for the three months ended March 31, 2014 and 2013. The tax years 2005 through 2012 remain open to examination by the major taxing jurisdictions to which the Company is subject.

Basic_and_Diluted_Net_Loss_Per

Basic and Diluted Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2014
Basic and Diluted Net Loss Per Common Share	'
Basic and Diluted Net Loss Per Common Share	'
	9. Basic and Diluted Net Loss Per Common Share
	Basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, excluding the dilutive effects of converting options and restricted stock units outstanding. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the potential dilutive effects of options and restricted stock units outstanding during the period calculated in accordance with the treasury stock method. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between weighted average number of shares used to calculate basic and diluted net loss per common share for the three months ended March 31, 2014 and 2013.
	The calculation of weighted average diluted shares outstanding excludes the dilutive effect of options and restricted stock units outstanding, as the impact of such items are anti-dilutive during periods of net loss.  Shares excluded from the calculation, prior to the use of the treasury stock method, unweighted, were 2,662,000 and 2,338,000 at March 31, 2014 and 2013, respectively.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies and Basis of Presentation	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.
Cash, Cash Equivalents and Marketable Securities	'
	Cash, Cash Equivalents and Marketable Securities
	All highly liquid securities with maturities of 90 days or less from the date of purchase are considered to be cash equivalents. As of March 31, 2014 and December 31, 2013, cash and cash equivalents were comprised of funds invested in cash and money market accounts. The Company maintains cash balances in excess of amounts insured by the FDIC. The accounts are monitored by management to mitigate the risk.
	Investments with maturities of more than 90 days from the date of purchase are considered marketable securities. Marketable securities are stated at fair value. The Company has classified its entire marketable securities portfolio as available-for-sale securities. Accordingly, any unrealized gain or loss on the investments is reported as a component of accumulated other comprehensive income (loss). The amortized cost of these securities is adjusted for amortization of premiums and accretion of discounts to maturity, as applicable. Such amortizations and accretions are included as a component of interest income. The entire marketable securities portfolio is considered available for use in current operations and, accordingly, all such investments are considered current assets although the stated maturity of individual investments may be one year or more beyond the balance sheet date.
	Realized gains and losses, determined on a specific identification basis, and declines in value, if any, judged to be other-than-temporary on available-for-sale securities are reported as a component of interest income. When securities are sold, any associated unrealized gain or loss previously reported in accumulated other comprehensive income (loss) is reclassified out of stockholders’ equity and recorded in the statement of operations and comprehensive loss for the period. Accrued interest and dividends are included in interest income.
	On a quarterly basis, the Company reviews the available-for-sale securities for other-than-temporary declines in fair value below the amortized cost basis.  This evaluation is based on a number of factors including the length of time and extent to which the fair value has been below the cost basis and any adverse conditions related specifically to the security, including any changes to the credit rating of the security. If the Company concludes that an other-than-temporary impairment exists, it recognizes an impairment charge to reduce the investment to fair value and records the related charge as a reduction of interest income. No impairment charges were recognized for the three months ended March 31, 2014 and 2013.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at historical cost and consisted of the following:
		March 31,			December 31,
		2014			2013
	Cameras	$	923,000		$	923,000
	Computer hardware and electronics	214,000			182,000
	Furniture and fixtures	244,000			234,000
	Software	21,000			21,000
		1,402,000			1,360,000
	Less accumulated depreciation	(1,294,000		)	(1,266,000		)
		$	108,000		$	94,000
	Depreciation is recorded using the straight-line method over the estimated useful lives of the assets (one to five years). The Company reviews its property and equipment assets for impairment in value whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company had no impairments or disposals during the three months ended March 31, 2014 and 2013.
	Cameras were used in our clinical trials, are fully depreciated as of March 31, 2014 and are being held for disposal.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. We do not enter into any investment transaction for trading or speculative purposes.
	The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by U.S. government and U.S. government agencies and corporate debt securities and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC. The accounts are monitored by management to mitigate the risk.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) is comprised of net loss and other comprehensive income (loss). For the three months ended March 31, 2014 and 2013, the only component of other comprehensive income (loss) are net unrealized gains and losses on marketable securities. There were no reclassifications out of accumulated other comprehensive income (loss) during the three months ended March 31, 2014 and 2013.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts reported in the accompanying condensed consolidated financial statements for accounts payable and accrued liabilities approximate their fair value because of the short-term nature of these accounts. The fair value of cash equivalents, marketable securities and the notes payable are discussed in Note 7, “Fair Value Measurements.”
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2013, a new accounting standard was issued that requires companies to present in the financial statements an unrecognized tax benefit as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. This standard was adopted prospectively beginning on January 1, 2014 and did not have a material impact on the Company’s consolidated financial statements and related disclosures.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies and Basis of Presentation	'
Schedule of property and equipment recorded at historical cost	'
		March 31,			December 31,
		2014			2013
	Cameras	$	923,000		$	923,000
	Computer hardware and electronics	214,000			182,000
	Furniture and fixtures	244,000			234,000
	Software	21,000			21,000
		1,402,000			1,360,000
	Less accumulated depreciation	(1,294,000		)	(1,266,000		)
		$	108,000		$	94,000

Marketable_Securities_Tables

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2014
Marketable Securities	'
Schedule of marketable securities held	'
	Type of security as of March 31, 2014	Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair
				Gains		Losses			Value
	U.S. government agency securities	$	2,000,000	$	2,000	$	—		$	2,002,000
	Corporate debt securities:
	Financial	37,255,000		9,000		(1,000		)	37,263,000
	Industrial	10,025,000		8,000		(4,000		)	10,029,000
	Other	8,942,000		—		(6,000		)	8,936,000
	Total available-for-sale securities	$	58,222,000	$	19,000	$	(11,000	)	$	58,230,000
	Type of security as of December 31, 2013	Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair
				Gains		Losses			Value
	U.S. government agency securities	$	2,000,000	$	3,000	$	—		$	2,003,000
	Corporate debt securities:
	Financial	33,192,000		13,000		(5,000		)	33,200,000
	Industrial	11,081,000		2,000		(3,000		)	11,080,000
	Other	9,263,000		—		(6,000		)	9,257,000
	Total available-for-sale securities	$	55,536,000	$	18,000	$	(14,000	)	$	55,540,000
Schedule of maturities of the entity's marketable securities	'
		March 31, 2014				December 31, 2013
		Amortized		Estimated Fair		Amortized			Estimated Fair
		Cost		Value		Cost			Value
	Mature in one year or less	$	50,760,000	$	50,774,000	$	33,279,000		$	33,293,000
	Mature after one year through two years	7,462,000		7,456,000		22,257,000			22,247,000
		$	58,222,000	$	58,230,000	$	55,536,000		$	55,540,000

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2014
Notes Payable	'
Schedule of notes payable	'
		March 31,			December 31,
		2014			2013
	Note payable to Bayer	$	21,645,000		$	—
	Notes payable related to credit facility	10,170,000			11,505,000
		31,815,000			11,505,000
	Less current portion	(5,652,000		)	(5,526,000		)
	Notes payable-net of current portion	$	26,163,000		$	5,979,000
Schedule of balance of the note payable to Bayer	'
		March 31, 2014
	Face value of note payable to Bayer	$	51,000,000
	Debt discount at date of issuance	(29,400,000		)
	Amortization of debt discount	45,000
	Note payable to Bayer	$	21,645,000

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity	'
Schedule of shares of the Company's common stock reserved for future issuance	'
		March 31,
		2014
	Common stock awards outstanding	2,662,000
	Common stock awards available for grant	631,000
	Total common shares reserved for future issuance	3,293,000
Schedule of equity-based compensation cost recorded in the statements of operations and comprehensive loss	'
		Three Months Ended
		March 31,
		2014			2013
	Research and development	$	1,488,000		$	506,000
	General and administrative	1,423,000			430,000
		$	2,911,000		$	936,000
Summary of stock option activity	'
		Number of		Weighted-
		Shares		Average
				Exercise Price
	Outstanding at December 31, 2013	2,273,000		$	14.85
	Granted	481,000		44.12
	Exercised	(195,000	)	5.55
	Cancelled	(35,000	)	21.92
	Outstanding at March 31, 2014	2,524,000		$	21.04
Summary of restricted stock unit activity	'
		Number of		Weighted-
		Shares		Average
				Grant-Date
				Fair Value
	Outstanding at December 31, 2013	63,000		$	27.16
	Granted	89,000		44.02
	Vested	(13,000	)	22.49
	Cancelled	(1,000	)	44.02
	Outstanding at March 31, 2014	138,000		$	38.35

Collaborations_and_Contingenci1

Collaborations and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2014
Collaborations and Contingencies	'
Schedule of acquisition date costs allocated to the acquired rights	'
	Fair value of common stock issued	$	31,429,000
	Fair value of note payable to Bayer	21,600,000
	Other	(272,000		)
	Total in-process research and development	$	52,757,000

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements	'
Schedule of fair value hierarchy about each major category of financial assets and liabilities measured at fair value on a recurring and non-recurring basis	'
		Fair Value Measurement at March 31, 2014 Using:
		Quoted Prices		Significant		Significant		Balance as of
		in Active		Other		Unobservable		March 31,
		Markets for		Observable		Inputs		2014
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Assets:
	Cash equivalents	$	87,818,000	$	—	$	—	$	87,818,000
	U.S. government agency securities	—		2,002,000		—		2,002,000
	Corporate debt securities	—		56,228,000		—		56,228,000
	Total	$	87,818,000	$	58,230,000	$	—	$	146,048,000
	Liabilities:
	Note payable to Bayer	—		—		21,645,000		21,645,000
	Total	$	—	$	—	$	21,645,000	$	21,645,000
		Fair Value Measurement at December 31, 2013 Using:
		Quoted Prices		Significant		Significant		Balance as of
		in Active		Other		Unobservable		December 31,
		Markets for		Observable		Inputs		2013
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Assets:
	Cash equivalents	$	95,537,000	$	—	$	—	$	95,537,000
	U.S. government agency securities	—		2,003,000		—		2,003,000
	Corporate debt securities	—		53,537,000		—		53,537,000
	Total	$	95,537,000	$	55,540,000	$	—	$	151,077,000

Organization_Details

Organization (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Organization	'
Charge for acquired in-process-research and development	$52,757,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies and Basis of Presentation (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Cash, Cash Equivalents and Marketable Securities	'	'	'
Impairment charges	$0	$0	'
Property and Equipment	'	'	'
Gross	1,402,000	'	1,360,000
Less accumulated depreciation	-1,294,000	'	-1,266,000
Net	108,000	'	94,000
Impairments or disposal of property and equipment	0	0	'
Minimum	'	'	'
Property and Equipment	'	'	'
Estimated useful lives	'1 year	'	'
Maximum	'	'	'
Property and Equipment	'	'	'
Estimated useful lives	'5 years	'	'
Cameras	'	'	'
Property and Equipment	'	'	'
Gross	923,000	'	923,000
Computer hardware and electronics	'	'	'
Property and Equipment	'	'	'
Gross	214,000	'	182,000
Furniture and fixtures	'	'	'
Property and Equipment	'	'	'
Gross	244,000	'	234,000
Software	'	'	'
Property and Equipment	'	'	'
Gross	$21,000	'	$21,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies and Basis of Presentation (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Comprehensive Income (Loss)	'	'
Reclassifications out of accumulated other comprehensive income (loss) related to marketable securities	$0	$0

Marketable_Securities_Details

Marketable Securities (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Marketable securities	'	'	'
Amortized Cost	$58,222,000	'	$55,536,000
Gross Unrealized Gains	19,000	'	18,000
Gross Unrealized Losses	-11,000	'	-14,000
Estimated Fair Value	58,230,000	'	55,540,000
Realized gains or losses from the sale of marketable securities	0	0	'
Aggregate fair value of available-for-sale investments that have been continuous unrealized loss position for less than 12 months	14,172,000	'	'
Amortized Cost	'	'	'
Mature in one year or less	50,760,000	'	33,279,000
Mature after one year through two years	7,462,000	'	22,257,000
Amortized cost	58,222,000	'	55,536,000
Estimated Fair Value	'	'	'
Mature in one year or less	50,774,000	'	33,293,000
Mature after one year through two years	7,456,000	'	22,247,000
Estimated Fair Value	58,230,000	'	55,540,000
U.S. government agency securities	'	'	'
Marketable securities	'	'	'
Amortized Cost	2,000,000	'	2,000,000
Gross Unrealized Gains	2,000	'	3,000
Estimated Fair Value	2,002,000	'	2,003,000
Estimated Fair Value	'	'	'
Estimated Fair Value	2,002,000	'	2,003,000
Financial	'	'	'
Marketable securities	'	'	'
Amortized Cost	37,255,000	'	33,192,000
Gross Unrealized Gains	9,000	'	13,000
Gross Unrealized Losses	-1,000	'	-5,000
Estimated Fair Value	37,263,000	'	33,200,000
Estimated Fair Value	'	'	'
Estimated Fair Value	37,263,000	'	33,200,000
Industrial	'	'	'
Marketable securities	'	'	'
Amortized Cost	10,025,000	'	11,081,000
Gross Unrealized Gains	8,000	'	2,000
Gross Unrealized Losses	-4,000	'	-3,000
Estimated Fair Value	10,029,000	'	11,080,000
Estimated Fair Value	'	'	'
Estimated Fair Value	10,029,000	'	11,080,000
Other	'	'	'
Marketable securities	'	'	'
Amortized Cost	8,942,000	'	9,263,000
Gross Unrealized Losses	-6,000	'	-6,000
Estimated Fair Value	8,936,000	'	9,257,000
Estimated Fair Value	'	'	'
Estimated Fair Value	$8,936,000	'	$9,257,000

Notes_Payable_Details

Notes Payable (Details) (USD $)

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Dec. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 21, 2011

Dec. 31, 2011

Feb. 28, 2013

Jan. 31, 2013

Oct. 02, 2012

Nov. 30, 2012

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 21, 2011

Mar. 31, 2014

Mar. 31, 2014

Series C redeemable convertible preferred stock warrants

Series D redeemable convertible preferred stock warrants

Notes payable related to credit facility

Notes payable related to credit facility

Notes payable related to credit facility

Notes payable related to credit facility

Notes payable related to credit facility

Notes payable related to credit facility

Notes payable related to credit facility

Notes payable related to credit facility

Note payable to Bayer

Note payable to Bayer

Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable

'

$31,815,000

'

$11,505,000

'

'

'

'

'

'

$10,170,000

'

$11,505,000

'

$21,645,000

$21,645,000

Less current portion

'

-5,652,000

'

-5,526,000

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable-net of current portion

'

26,163,000

'

5,979,000

'

'

'

'

'

'

'

'

'

'

'

'

Face amount of debt issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51,000,000

51,000,000

Interest rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

5.00%

Option to pay accrued interest in cash (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

Term of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

Fair value of note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,600,000

21,600,000

Assumed borrowing rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

Balance of the note payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Face value of note payable to Bayer

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51,000,000

51,000,000

Debt discount at date of issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-29,400,000

-29,400,000

Amortization of debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,000

Interest expense related to the notes payable

'

'

'

'

'

'

'

'

'

'

356,000

310,000

'

'

'

213,000

Accrued interest expense

'

660,000

'

375,000

'

'

'

'

'

'

492,000

'

375,000

'

168,000

168,000

Remaining unamortized discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29,355,000

29,355,000

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

Initial period of interest only payments

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

'

'

'

Fixed rate of interest in initial period (as a percent)

'

'

'

'

'

'

'

'

'

'

11.50%

'

'

'

'

'

Period of payment of interest and principal following the initial period

'

'

'

'

'

'

'

'

'

'

'30 months

'

'

'

'

'

Fixed rate of interest in period following initial period (as a percent)

'

'

'

'

'

'

'

'

'

'

8.50%

'

'

'

'

'

Final payment percentage

'

'

'

'

'

'

'

'

'

'

6.00%

'

'

'

'

'

Amount drawn under credit facility

'

'

'

'

'

'

5,000,000

5,000,000

5,000,000

'

'

'

'

'

'

'

Amount that the entity can draw, pursuant to the extension obtained

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

Amount outstanding under credit facility

'

15,000,000

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Remaining borrowing capacity

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued (in shares)

'

'

'

'

34,000

86,000

'

'

'

'

'

'

'

'

'

'

Exercise price (in dollars per unit)

'

'

'

'

$13.35

$13.90

'

'

'

'

'

'

'

'

'

'

Estimated fair value of warrants

'

'

'

'

345,000

1,074,000

'

'

'

'

'

'

'

'

'

'

Stock exercised upon issuance of warrants

49,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of debt discount and issuance cost

'

130,000

85,000

'

'

'

'

'

'

'

85,000

85,000

'

'

'

'

Unamortized debt issuance cost

'

'

'

'

'

'

'

'

'

'

$651,000

'

$736,000

'

'

'

Stockholders_Equity_Details

Stockholders' Equity (Details)	Mar. 31, 2014
Common Stock Reserved for Future Issuance	'
Common stock awards outstanding (in shares)	2,662,000
Common stock awards available for grant (in shares)	631,000
Total common shares reserved for future issuance	3,293,000

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Incentive stock options | Individuals owning more than 10% | Minimum	'	'
Stock Awards	'	'
Voting power of all classes of stock (as a percent)	10.00%	'
Incentive stock options | Individuals owning more than 10% | Maximum	'	'
Stock Awards	'	'
Expiration period	'5 years	'
Incentive stock options | 10% Stockholder	'	'
Stock Awards	'	'
Voting power of all classes of stock (as a percent)	10.00%	'
Incentive stock options | 10% Stockholder | Minimum	'	'
Stock Awards	'	'
Minimum exercise price as a percentage of fair market value	110.00%	'
Stock options	'	'
Stock Awards	'	'
Expiration period	'10 years	'
Stock options | Employees	'	'
Stock Awards	'	'
Vesting period	'4 years	'
2012 Equity Incentive Award	'	'
Stock Awards	'	'
Threshold number of annual additional shares of common stock available for issuance	1,512,687	'
Percentage for the threshold number of annual additional shares of common stock available for issuance, expressed as percentage of common stock issued and outstanding on last day of the preceding calendar year	4.00%	'
Number of shares authorized for grant	4,094,000	3,224,000

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock-based compensation expense	'	'
Total equity-based compensation cost	$2,911,000	$936,000
Stock options	'	'
Stock-based compensation expense	'	'
Unrecognized compensation expense	21,640,000	'
Expected weighted-average period of recognition	'3 years 1 month 20 days	'
Restricted stock units	'	'
Stock-based compensation expense	'	'
Unrecognized compensation expense	4,282,000	'
Expected weighted-average period of recognition	'1 year 6 months 4 days	'
Research and development	'	'
Stock-based compensation expense	'	'
Total equity-based compensation cost	1,488,000	506,000
General and administrative	'	'
Stock-based compensation expense	'	'
Total equity-based compensation cost	$1,423,000	$430,000

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (USD $)	3 Months Ended
	Mar. 31, 2014
Number of Shares	'
Outstanding at the end of the period (in shares)	2,662,000
Stock options	'
Number of Shares	'
Outstanding at the beginning of the period (in shares)	2,273,000
Granted (in shares)	481,000
Exercised (in shares)	-195,000
Cancelled (in shares)	-35,000
Outstanding at the end of the period (in shares)	2,524,000
Weighted-Average Exercise Price	'
Outstanding at the beginning of the period (in dollars per share)	$14.85
Granted (in dollars per share)	$44.12
Exercised (in dollars per share)	$5.55
Cancelled (in dollars per share)	$21.92
Outstanding at the end of the period (in dollars per share)	$21.04
Restricted stock units	'
Number of Shares	'
Outstanding at the beginning of the period (in shares)	63,000
Granted (in shares)	89,000
Vested (in shares)	-13,000
Cancelled (in shares)	-1,000
Outstanding at the end of the period (in shares)	138,000
Weighted-Average Grant-Date Fair Value	'
Outstanding at the beginning of the period (in dollars per share)	$27.16
Granted (in dollars per share)	$44.02
Vested (in dollars per share)	$22.49
Cancelled (in dollars per share)	$44.02
Outstanding at the end of the period (in dollars per share)	$38.35

Collaborations_and_Contingenci2

Collaborations and Contingencies (Details) (USD $)

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Mar. 31, 2014

Mar. 31, 2014

31-May-12

Aug. 31, 2010

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

31-May-12

Aug. 31, 2005

Dec. 31, 2010

Aug. 31, 2010

Unsecured promissory note

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

Bayer

Bayer

Bayer

Bayer

Bayer

Bayer

Bayer

LA Biomed

LA Biomed

LA Biomed

LA Biomed

item

KYTHERA Holdings Ltd.

KYTHERA Holdings Ltd.

KYTHERA Holdings Ltd.

Maximum

Unsecured promissory note

Collaboration Arrangements

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront license fee paid

'

'

'

$21,319,000

'

'

'

'

'

'

'

'

'

Contingent income

'

'

'

297,000,000

'

'

'

'

'

'

'

'

'

Contingent income received

'

'

15,800,000

'

'

'

'

'

'

'

'

'

'

Number of consecutive validated manufacturing lots

'

'

2

'

'

'

'

'

'

'

'

'

'

Restricted cash

'

'

17,400,000

22,247,000

'

'

'

'

'

'

'

'

'

Deferred development funds

'

'

17,400,000

22,247,000

'

'

967,000

'

'

'

'

'

'

Amounts recognized as offsets to research and development expenses

'

'

'

'

2,391,000

3,095,000

'

'

'

'

'

'

'

Amounts recognized as offsets to in process research and development expenses

'

'

'

'

'

'

695,000

'

'

'

'

'

'

Number of common stock issued as a part of consideration

'

'

'

'

'

'

698,103

'

'

'

'

'

'

Value of common stock issued as a part of consideration

'

'

'

'

'

'

33,000,000

'

'

'

'

'

'

Average closing stock price (in dollars per share)

'

'

'

'

'

'

$47.27

'

'

'

'

'

'

Notes issued as a part of consideration

'

51,000,000

'

'

'

'

51,000,000

'

'

'

'

'

'

Interest rate (as a percent)

'

5.00%

'

'

'

'

5.00%

'

'

'

'

'

'

Consideration upon the achievement of certain long-term sales milestone payments on annual sales

'

'

'

'

'

'

'

123,800,000

'

'

'

'

'

Acquisition date costs allocated to the acquired rights

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of common stock issued

'

'

'

'

'

'

31,429,000

'

'

'

'

'

'

Fair value of note payable to Bayer

'

'

'

'

'

'

'

'

21,600,000

'

'

'

'

Other

'

'

'

'

'

'

-272,000

'

'

'

'

'

'

In-process research and development

52,757,000

'

'

'

'

'

52,757,000

'

'

'

'

'

'

Closing price of common stock (in dollars per share)

'

'

'

'

'

'

$45.02

'

'

'

'

'

'

Fair value of note payable to Bayer

'

'

'

'

'

'

'

'

21,600,000

'

'

'

'

Assumed borrowing rate (as a percent)

'

15.00%

'

'

'

'

'

'

15.00%

'

'

'

'

Milestone payment

'

'

'

'

'

'

'

'

'

'

500,000

'

'

Non-royalty sublicense fees equal to a certain percentage of sublicense income

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

Maximum non-royalty sublicense fees

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

Right to issue capital to satisfy payment of sublicense fees (as a percent)

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

Non-royalty sublicense fee expenses

'

'

'

'

'

'

'

'

'

1,580,000

'

'

1,950,000

Non-royalty sublicense fee paid

'

'

'

'

'

'

'

'

'

'

'

390,000

'

Remainder of non-royalty sublicense fee

'

'

'

'

'

'

'

'

'

'

'

$1,560,000

'

Non-royalty sublicense fee paid in cash upon initial public offering (as a percent)

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

Non-royalty sublicense fee paid in stock upon initial public offering (as a percent)

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Note payable to Bayer

U.S. government agency securities and Corporate debt securities

U.S. government agency securities

U.S. government agency securities

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Significant Other Observable Inputs (Level 2)

Significant Other Observable Inputs (Level 2)

Significant Other Observable Inputs (Level 2)

Significant Other Observable Inputs (Level 2)

Significant Other Observable Inputs (Level 2)

Significant Other Observable Inputs (Level 2)

Significant Unobservable Inputs (Level 3)

Total

Total

Total

Total

Total

Total

Total

U.S. government agency securities

U.S. government agency securities

Corporate debt securities

Corporate debt securities

Bayer

Bayer

U.S. government agency securities

U.S. government agency securities

Corporate debt securities

Corporate debt securities

Fair value of financial assets and liabilities measured at fair value on a recurring and non-recurring basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustment made to U.S. Treasury securities

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum maturity period

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate (as a percent)

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate (as a percent)

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value assets, amount transferred between measurement levels

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value liabilities, amount transferred between measurement levels

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash equivalents

'

'

'

'

'

'

'

87,818,000

95,537,000

'

'

'

'

'

'

'

87,818,000

95,537,000

'

'

'

'

'

Marketable securities

58,230,000

55,540,000

'

'

'

2,002,000

2,003,000

'

'

'

'

2,002,000

2,003,000

56,228,000

53,537,000

'

'

'

'

2,002,000

2,003,000

56,228,000

53,537,000

Total

'

'

'

'

'

'

'

87,818,000

95,537,000

58,230,000

55,540,000

'

'

'

'

'

146,048,000

151,077,000

'

'

'

'

'

Liabilities:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,645,000

'

'

21,645,000

'

'

'

'

Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$21,645,000

$21,645,000

'

'

'

'

'

'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Income Taxes	'
Provision for income taxes	$0

Basic_and_Diluted_Net_Loss_Per1

Basic and Diluted Net Loss Per Common Share (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Basic and Diluted Net Loss Per Common Share	'	'
Shares excluded from the calculation of net loss per common share, prior to the use of the treasury stock method, unweighted	2,662,000	2,338,000